{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Solid+Tumor&page=2", "query": { "condition": "Pediatric Solid Tumor", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pediatric+Solid+Tumor&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:22:53.926Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00458887", "title": "Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ototoxicity", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 301, "start_date": "2007-05", "completion_date": "2017-02-28", "has_results": false, "last_update_posted_date": "2017-03-13", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458887" }, { "nct_id": "NCT02982941", "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Rhabdomyosarcoma", "Osteosarcoma", "Ewing Sarcoma", "Wilms Tumor", "Desmoplastic Small Round Cell Tumor" ], "interventions": [ { "name": "Enoblituzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "35 Years", "sex": "ALL", "summary": "1 Year to 35 Years" }, "enrollment_count": 25, "start_date": "2016-12", "completion_date": "2019-05-22", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 6, "location_summary": "Palo Alto, California • Bethesda, Maryland • Philadelphia, Pennsylvania + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02982941" }, { "nct_id": "NCT00281944", "title": "Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Central Nervous System Choriocarcinoma", "Childhood Central Nervous System Embryonal Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Central Nervous System Germinoma", "Childhood Central Nervous System Mixed Germ Cell Tumor", "Childhood Central Nervous System Teratoma", "Childhood Central Nervous System Yolk Sac Tumor", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Central Nervous System Embryonal Tumor", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 42, "start_date": "2005-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-03", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00281944" }, { "nct_id": "NCT02574728", "title": "Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Sirolimus", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 46, "start_date": "2015-06", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Wilmington, Delaware • Atlanta, Georgia + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Wilmington", "state": "Delaware" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574728" }, { "nct_id": "NCT04337177", "title": "Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Neuroblastoma", "Rhabdomyosarcoma", "Ewing Sarcoma", "Hepatoblastoma", "Medulloblastoma" ], "interventions": [ { "name": "VAL-413", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Valent Technologies, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 20, "start_date": "2021-10-25", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 11, "location_summary": "Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04337177" }, { "nct_id": "NCT00402935", "title": "Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leukemia", "Long-term Effects Secondary to Cancer Therapy in Adults", "Long-term Effects Secondary to Cancer Therapy in Children", "Lymphoma", "Sexual Dysfunction and Infertility", "Sexuality and Reproductive Issues", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "fertility assessment and management", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "ultrasound imaging", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "35 Years", "sex": "FEMALE", "summary": "14 Years to 35 Years · Female only" }, "enrollment_count": 0, "start_date": "2004-02", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2012-03-20", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402935" }, { "nct_id": "NCT00005811", "title": "Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "AIDS-related Small Noncleaved Cell Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "HIV-associated Hodgkin Lymphoma", "Leptomeningeal Metastases", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 77, "start_date": "2000-04", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2013-02-21", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005811" }, { "nct_id": "NCT03936465", "title": "Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Childhood", "Lymphoma", "Brain Tumor, Pediatric" ], "interventions": [ { "name": "BMS-986158", "type": "DRUG" }, { "name": "BMS-986378", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 41, "start_date": "2019-09-27", "completion_date": "2024-10-01", "has_results": false, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 5, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Durham, North Carolina + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03936465" }, { "nct_id": "NCT03837899", "title": "Durvalumab and Tremelimumab for Pediatric Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pediatric Cancer", "Solid Tumor Pediatric", "Hematological Malignancies" ], "interventions": [ { "name": "Durvalumab / Tremelimumab Combination Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "0 Years to 18 Years" }, "enrollment_count": 50, "start_date": "2019-03-07", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 5, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03837899" }, { "nct_id": "NCT04678427", "title": "Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "6 Minute Walk Functional Test", "type": "OTHER" }, { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Timed Get Up and Go Test", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "6 Years to 29 Years" }, "enrollment_count": 60, "start_date": "2020-11-13", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-21T23:22:53.926Z", "location_count": 2, "location_summary": "Dallas, Texas • Houston, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678427" } ] }